InvestorsHub Logo
icon url

MayoMobile

08/31/22 1:40 PM

#372218 RE: MayoMobile #372216

By the way, this is best viewed on a computer.
icon url

Investor2014

09/01/22 11:41 AM

#372327 RE: MayoMobile #372216

Maybe this will help.

Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system

A critical element of the long-term consequence of the regulation of synaptic signaling at the cellular level is probably that of transcriptional regulation. In addition to influencing neurotransmitter release, a role for nAChRs in the regulation of cell signaling and gene expression has been reported52. In neuroblastoma cells, exposure to nicotine influences the expression of a diverse set of genes, including transcription and protein-processing factors, and proteins associated with RNA binding and the plasma membrane53. For nAChRs, such transcriptional control is usually triggered by calcium influx directly through the receptors, indirectly through VDCCs, and through release from internal stores4, 54, 55, 56, 57, 58.

Regulation of neurotransmitter release The activation of nAChRs can influence gene expression for immediate early genes and genes involved in transmitter synthesis15, 52, 59, 60. In the chick ciliary ganglion61, the nAChR-mediated control of transcription relies on calcium influx and calcium release from internal stores to activate first CaMKII/IV, and then ERK/MAPK. These enzymes activate the transcription factor CREB (the cAMP response element-binding protein), which can alter gene expression.

icon url

georgejjl

09/02/22 9:37 PM

#372509 RE: MayoMobile #372216

Question for MayoMobile and falconer66a

See the paper at the link below regarding the 52 week and 148 week results for the Blarcamesine Phase 2a trial for treating mild to moderate Alzheimer's disease.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/

Supplementary Figure 4: Exceptional therapeutic response
Longitudinal change in MMSE and ADCS-ADL over 148 weeks of combined studies of two patients (a and b) having SIGMAR1 gene wild type, mean high concentration levels of ANAVEX2-73 in plasma in Part B and baseline MMSE ≥20. All n=6 subjects, including patients a and b, with these response characteristics are shown in Figure 3.

An additional ten patients had “unexpected positive benefit” described by their investigator in the CRF data e.g. improved mood, increase attention, improved sleep. Eight of these patients recorded a high ANAVEX2-73 plasma concentration (≥4.0ng/ml) in Part B.



We can see that the participants that responded best GROUP1 had the following characteristics:
Baseline MMSE score of greater than or equal to 20
Sigmar1 wild type
High mean (arithmetic average) concentration of Anavex 2-73 taken orally
APOE3 and/or APOE2 alleles


Now we know that the Phase 2b/3 trial was for the treatment of participants with early stage Alzheimer's disease with the following characteristics:
Baseline MMSE score of greater or equal to 20
On average 1/3 of the 509 subjects were taking the high dose of Blarcamesine which is intended to achieve a concentration of Anavex 2-73 of greater than 4 ng/ml


What does this tell us regarding the probability of success of this trial?

Good luck and GOD bless,